CNS Updates Results from On-Going Potentially Pivotal Glioblastoma Study

 Data presented at the 2023 SNO/ASCO CNS Cancer Conference

Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) with topline data from interim analysis expected before year end

https://www.biospace.com/article/releases/cns-pharmaceuticals-nasdaq-cnsp-presents-updated-results-from-on-going-potentially-pivotal-study-of-berubicin-in-adult-patients-with-recurrent-gbm-who-grade-iv-after-failure-of-standard-first-line-therapy/